Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
- CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
- 05/29/2025
|
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer
- CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
- 05/28/2025
|
Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript
- Wave Life Sciences Ltd. (NASDAQ:WVE ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Erik Ingelsson - Chief Scientific Officer Kyle Moran - Chief Financial Officer Conference Call Participants Joon Lee - Truist Securities Salim Syed - Mizuho Catherine Novack - Jones Research Ananda Ghosh - HC Wainwright and Company Lisa Walter - RBC Madison El-Saadi - B.
- 05/09/2025
|
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
- Wave Life Sciences (WVE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.24 per share a year ago.
- 05/08/2025
|
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
- Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon 53 amenable DMD including statistically significant and clinically meaningful improvement in TTR, substantial improvements in muscle health; NDA submission for accelerated approval with monthly dosing planned for 2026 IND submission expected 2H 2025 for potentially registrational WVE-003 Phase 2/3 study in HD with caudate atrophy as a primary endpoint Cash and cash equivalents of $243.1 million as of March 31, 2025, with runway expected into 2027 Investor conference call and webcast at 8:30 a.m. ET today CAMBRIDGE, Mass.
- 05/08/2025
|
Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for
- Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/01/2025
|
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
- CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company's first quarter 2025 financial results and provide business updates.
- 05/01/2025
|
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
- Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
- 03/28/2025
|
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531
- Wave Life Sciences Ltd. release of multi-dose data from the phase 1b/2a open-label RestorAAtion-2 study, using WVE-006 for AATD-related lung disease, expected in 2025. Positive results were achieved in the phase 2 FORWARD-53 study, using WVE-N531 for the treatment of patients with DMD amenable to exon 53 skipping; an average dystrophin expression of 7.8% was achieved. The Duchenne Muscular Dystrophy market, in the 7 major markets, will reach $5.2 billion by 2033.
- 03/27/2025
|
Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar?
- Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 03/27/2025
|
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year
- Wave Life Sciences Ltd. WVE released data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon-skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
- 03/26/2025
|
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
- Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA
- 03/26/2025
|
Wave Life Sciences Ltd. (WVE) Q4 2024 Earnings Call Transcript
- Wave Life Sciences Ltd. (NASDAQ:WVE ) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Kate Rausch - VP, IR & Corporate Affairs Paul Bolno - President & CEO Erik Ingelsson - Chief Scientific Officer Kyle Moran - Chief Financial Officer Conference Call Participants Ron Feiner - JPMorgan Salim Syed - Mizuho Joon Lee - Truist Securities Joe Schwartz - Leerink Partners Roger Song - Jefferies Catherine Novack - Jones Trading Ryan Deschner - Raymond James Madison El-Saadi - B.
- 03/04/2025
|
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort
- 03/04/2025
|
Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
- CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, March 4, 2025, to review the company's fourth quarter and full year 2024 financial results and provide business updates.
- 02/25/2025
|
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
- WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation)
- 02/06/2025
|
Wave Life Sciences Is A Buy On Pipeline Prospects
- Wave Life Sciences develops stereopure oligonucleotides targeting genetic mutations, with lead assets in DMD, AATD, and Huntington's Disease showing promising data. Major collaborations with GSK and positive trial results have significantly boosted WVE's stock, despite previous flat performance and management missteps. Financially strong with $525M in cash, the Company has a solid runway for 8–10 quarters, though approval for its programs is still years away.
- 01/08/2025
|
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
- WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration
- 12/23/2024
|
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 9:45 a.m. PT / 12:45 p.m. ET.
- 12/16/2024
|
Wave Life Sciences to Present at Jefferies London Healthcare Conference
- CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET.
- 11/15/2024
|
Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Transcript
- Wave Life Sciences Ltd. (NASDAQ:WVE ) Q3 2024 Results Conference Call November 12, 2024 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Steven Seedhouse - Raymond James Joon Lee - Truist Salim Syed - Mizuho Luca Issi - RBC Catherine Novack - Jones Trading Madison El-Saadi - B.
- 11/12/2024
|
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates
- Wave Life Sciences (WVE) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.07 per share a year ago.
- 11/12/2024
|
Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?
- Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/05/2024
|
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
- WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s
- 10/30/2024
|
Wall Street Analysts Predict a 34.53% Upside in Wave Life Sciences (WVE): Here's What You Should Know
- The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Wave Life Sciences (WVE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 10/28/2024
|
1 Brand-New Big Reason to Buy This Biotech Stock Right Now
- This stock currently has a good balance of risk and potential rewards.
- 10/24/2024
|
What Makes Wave Life Sciences (WVE) a Strong Momentum Stock: Buy Now?
- Does Wave Life Sciences (WVE) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 10/23/2024
|
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
- Shares of Korro Bio and Wave Life Sciences diverged Monday after an analyst argued Korro is the better way to play the RNA-editing space.
- 10/21/2024
|
Wave Life Sciences Rockets 70% on Historic RNA Editing Success
- Wave Life Sciences Ltd. NASDAQ: WVE is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
- 10/18/2024
|
WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data
- Wave Life Sciences' stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the phase Ib/IIa study of WVE-006 for AATD.
- 10/17/2024
|
Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?
- Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 10/17/2024
|
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
- Wave Life Sciences announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of alpha-1 antitrypsin deficiency patients. A single subcutaneous administration of 200 mg of WVE-006 resulted in the presence of wild-type alpha-1 antitrypsin protein; This led to a more than 60% increase of AAT. The global Alpha-1 Antitrypsin Deficiency market is expected to reach a $10 billion market value by 2033.
- 10/16/2024
|
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
- Wave Life Sciences Ltd. WVE stock is trading higher on Wednesday after the company revealed proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency (AATD), an inherited genetic disorder that causes low levels of a protein (AAT) that protects the lungs.
- 10/16/2024
|
Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere
- Shares of Wave Life Sciences surged Wednesday after the company announced "impressive" proof-of-concept results for its new technology.
- 10/16/2024
|
Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024
- Event will highlight WVE-006 for AATD and Wave's rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE program for obesity Event will highlight WVE-006 for AATD and Wave's rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE program for obesity
- 10/16/2024
|
How Much Upside is Left in Wave Life Sciences (WVE)? Wall Street Analysts Think 89.71%
- The mean of analysts' price targets for Wave Life Sciences (WVE) points to an 89.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 10/11/2024
|
An Airline, Biotechs, and More See Huge Insider Buying
- 24/7 Wall St. Insights Public offerings of stock and activist investor activity have prompted some huge insider buying.
- 10/06/2024
|
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
- These two could become direct competitors relatively soon.
- 10/03/2024
|
Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
- CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it closed its previously announced underwritten public offering, and that the underwriters exercised in full their option to purchase an additional 3,750,000 of its ordinary shares at the public offering price of $8.00 per ordinary share, less underwriting discounts and commissions. After giving effect to the full exercise of the underwriters' option to purchase additional shares, the total number of ordinary shares sold in the offering is 26,875,001 ordinary shares which, along with the sale of pre-funded warrants to purchase 1,875,023 ordinary shares, resulted in aggregate gross proceeds to Wave Life Sciences of approximately $230 million, before deducting underwriting discounts and commissions and offering expenses.
- 10/01/2024
|
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
- CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan 8th Annual Genetic Medicines Conference in New York City on Tuesday, October 1, 2024, at 1:00 p.m. ET.
- 09/30/2024
|
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small pharmaceutical companies like Wave Life Sciences WVE, whose shares rose 9% the day after the central bank reduced rates by 50 basis points.
- 09/26/2024
|
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today the pricing of its previously announced underwritten public offering of 23,125,001 of its ordinary shares at a price to the public of $8.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 1,875,023 ordinary shares at an offering price of $7.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant.
- 09/25/2024
|
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study
- Wave Life Sciences stock soars 53% on positive interim data from a mid-stage study showing superior efficacy of investigational DMD drug, WVE-N531.
- 09/25/2024
|
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
- CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it has commenced an underwritten public offering of $175 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold in the public offering on the same terms and conditions. All of the securities in the offering will be sold by Wave Life Sciences.
- 09/24/2024
|
Wave Life Sciences' stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial
- Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.
- 09/24/2024
|
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
- Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two isoforms consistent with Becker muscular dystrophy patients who display milder disease
- 09/24/2024
|
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small pharmaceutical companies like Wave Life Sciences NASDAQ: WVE, whose shares rose 9% the day after the central bank reduced rates by 50 basis points.
- 09/20/2024
|
Wave Life Sciences Ltd. (WVE) Q2 2024 Earnings Call Transcript
- Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Erik Ingelsson - Chief Scientific Officer Conference Call Participants Tiago Fauth - Wells Fargo Joseph Schwartz - Leerink Partners Steven Seedhouse - Raymond James Luca Issi - RBC Salim Syed - Mizuho Joon Lee - Truist Operator Good morning, and welcome to the Wave Life Sciences Second Quarter 2024 Financial Results Conference Call.
- 08/10/2024
|
Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates
- Wave Life Sciences (WVE) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.20 per share a year ago.
- 08/08/2024
|
Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
- Successful clinical translation of Wave's RNA medicines platform in HD patients with WVE-003 provides further validation of Wave's proprietary platform with PN and stereochemistry; opt-in package for WVE-003 submitted to partner Takeda and engagement with regulators initiated to discuss potential path to accelerated approval
- 08/08/2024
|
Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024
- CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 8, 2024, to review the company's second quarter 2024 financial results and provide business updates.
- 08/01/2024
|
What's Going On With Wave Life Sciences Stock On Tuesday?
- Wave Life Sciences Ltd WVE announced results from its Phase 1b/2a SELECT-HD trial of WVE-003, which is being developed as a potential disease-modifying therapeutic for Huntington's disease (HD).
- 06/25/2024
|
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
- Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave's INHBE program as a best-in-class approach for obesity designed to induce fat burning and preserve muscle mass with once or twice-annual subcutaneous administration
- 06/12/2024
|
Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference
- CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 2024 Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2024, at 7:30 a.m. ET.
- 05/30/2024
|
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
- RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD remains on track for 2024
- 05/09/2024
|
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
- Appointment builds on Wave's recent progress advancing innovative genetic targets, such as INHBE, and continues to add significant experience to accelerate the rapid identification and translation of unique genetic insights into medicines Appointment builds on Wave's recent progress advancing innovative genetic targets, such as INHBE, and continues to add significant experience to accelerate the rapid identification and translation of unique genetic insights into medicines
- 05/09/2024
|
Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
- CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 14, 2024, at 8:30 a.m. ET.
- 05/07/2024
|
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
- CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 9, 2024, to review the company's first quarter 2024 financial results and provide business updates.
- 05/02/2024
|
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
- Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024 Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024
- 04/30/2024
|
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
- GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNAc-siRNA format with potential for best-in-class potency and durability
- 04/23/2024
|
Wave Life Sciences to Present at Upcoming Investor Conferences
- CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in April.
- 03/27/2024
|
Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032
- Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development include elastase inhibitors, novel augmentation therapy, RNA editing, gene therapy, and RNA interference.
- 03/14/2024
|
Wave Life Sciences Ltd. (WVE) Q4 2023 Earnings Call Transcript
- Wave Life Sciences Ltd. (NASDAQ:WVE ) Q4 2023 Earnings Call Transcript March 6, 2024 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Timur Ivannikov - Raymond James Salim Syed - Mizuho Joon Lee - Truist Joseph Schwartz - Leerink Partners Luca Issi - RBC Capital Andrew Fein - H.C.
- 03/06/2024
|
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-six-month or annual subcutaneous dosing; clinical trial initiation expected 1Q 2025
- 03/06/2024
|
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
- CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 6, 2024, to review the company's fourth quarter and full year 2023 financial results and provide business updates.
- 02/28/2024
|
Wave Life Sciences (WVE) Surges 10.9%: Is This an Indication of Further Gains?
- Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 02/28/2024
|
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
- Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which are important for potential muscle regeneration
- 02/27/2024
|
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
- Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans
- 01/08/2024
|
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 3:00 p.m. PT / 6:00 p.m. ET.
- 01/03/2024
|
Penny Stocks To Buy Now? 4 To Watch Before 2024
- As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023's ups and downs; maybe not.
- 12/19/2023
|
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
- FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024 Previous clinical proof-of-concept data demonstrated highest level of exon skipping ever observed in the clinic and that WVE-N531 was present in myogenic stem cells, which are important for potential muscle regeneration CAMBRIDGE, Mass., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
- 12/15/2023
|
Wave Life Sciences stock slides 31% after company prices $100 million secondary share offering
- Wave Life Sciences Ltd.'s stock WVE, -30.57% tumbled 31% Thursday, after the clinical-stage pharma company priced a $100 million secondary share offering at $5 a share, or a discount over its closing price Wednesday at $6.87.
- 12/07/2023
|
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
- CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public offering of 20,000,000 of its ordinary shares at a price to the public of $5.00 per ordinary share. Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 of its ordinary shares on the same terms and conditions. The offering is expected to close on or about December 11, 2023, subject to customary closing conditions.
- 12/07/2023
|
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
- CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has commenced an underwritten public offering of $100 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and pre-funded warrants sold in the public offering on the same terms and conditions. All of the securities in the offering will be sold by Wave Life Sciences.
- 12/06/2023
|
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
- CAMBRIDGE, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 6th Annual Evercore ISI HealthCONx Conference in Miami, FL on Wednesday, November 29, 2023 at 3:50 p.m. ET.
- 11/22/2023
|
Wave Life Sciences Ltd. (WVE) Q3 2023 Earnings Call Transcript
- Wave Life Sciences Ltd. (NASDAQ:WVE ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Steve Seedhouse - Raymond James Salim Syed - Mizuho Joseph Schwartz - Leerink Partners Eun Yang - Jefferies Operator Good morning and welcome to Wave Life Sciences Third Quarter 2023 Financial Results Conference Call.
- 11/10/2023
|
Wave Life Sciences (WVE) Soars 8.7%: Is Further Upside Left in the Stock?
- Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 09/29/2023
|
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
- CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the Chardan 7th Annual Genetic Medicines Conference in New York City on Monday, October 2, 2023. Dr. Bolno will participate in the ADAR Editing Panel at 9:30 a.m. ET and an analyst-led fireside chat at 10:30 a.m. ET.
- 09/25/2023
|
2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss
- Gene-editing therapies are among the most powerful medicines to ever exist. Wave Life Sciences is taking aim at two rare diseases, but it's short on cash.
- 09/19/2023
|
Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash
- Wave Life Sciences Ltd. develops stereopure oligonucleotides targeting disease-causing genetic mutations. The company has lead assets in phase 1/2 trials for Duchenne muscular dystrophy and Huntington's Disease. Wave has collaborations with GSK and Takeda, with the GSK deal potentially worth up to $3.3 billion in milestone payments.
- 09/12/2023
|
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a virtual analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will be available to view beginning on Monday, September 11, 2023, at 7:00 a.m. ET.
- 09/06/2023
|
WAVE Life Sciences Ltd. Sees a 23% Stock Price Surge Over the Past Three Months
- WAVE Life Sciences Ltd. ( WVE , Financial), a preclinical biopharmaceutical company, has seen a significant increase in its stock price over the past three months.
- 08/23/2023
|
Wave Life Sciences Ltd. (WVE) Q2 2023 Earnings Call Transcript
- Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President and Chief Executive Officer Anne Cheung - Chief Development Officer Kyle Moran - CFO Conference Call Participants Steven Seedhouse - Raymond James Julian Pino - Stifel Eun Yang - Jefferies Salim Syed - Mizuho Operator Good morning, and welcome to the Wave Life Sciences Second Quarter 2023 Financial Results Conference Call.
- 08/06/2023
|
Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates
- Wave Life Sciences (WVE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.62 per share a year ago.
- 08/03/2023
|
Wave Life Sciences: Less Certainty On Clinical Programs (Rating Downgrade)
- Wave Life Sciences: Less Certainty On Clinical Programs (Rating Downgrade)
- 06/21/2023
|
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
- Wave Life Sciences (WVE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.62 per share a year ago.
- 05/03/2023
|
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
- CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Guggenheim Genomic Medicines and Rare Disease Days in New York City on Monday, April 3, 2023 at 2:10 p.m. ET.
- 03/29/2023
|
Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates
- Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.90% and 47.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/22/2023
|
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
- CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 22, 2023, to discuss the company's fourth quarter and full year 2022 financial results and provide a business update.
- 03/02/2023
|
Wave Life Sciences (WVE) Upgraded to Buy: Here's What You Should Know
- Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 02/14/2023
|
After Plunging -23.26% in 4 Weeks, Here's Why the Trend Might Reverse for Wave Life Sciences (WVE)
- Wave Life Sciences (WVE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 02/14/2023
|
Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
- CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the SVB Securities Global Biopharma Conference at 10:00 a.m. ET on Thursday, February, 16, 2023.
- 02/09/2023
|
Wave Life Sciences: Huntington's Hypotheses, GSK Collaboration Catalysts To Move The Needle
- Wave Life Sciences caught a strong bid throughout the bulk of 2022, with the trend extending into the new year. Its novel hypothesis in Huntington's disease has piqued our interest most.
- 01/08/2023
|
MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An Edge
- Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining over 10% in less than a week of trading days has reached 235 out of 293 trading weeks (80.4%) not counting multiple gainers.
- 01/02/2023
|
All You Need to Know About Wave Life Sciences (WVE) Rating Upgrade to Buy
- Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 12/30/2022
|
4 Drug Stocks That More Than Doubled This Year
- We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.
- 12/30/2022
|
Wave, GSK enter strategic collaboration
- Shares of Wave Life Sciences Ltd. WVE, -7.20% jumped about 17% in premarket trading on Tuesday after the company announced a four-year strategic collaboration with GlaxoSmithKline GSK, -0.72% to develop oligonucleotide therapeutics.
- 12/13/2022
|
Wave Life Sciences Ltd. (WVE) Q3 2022 Earnings Call Transcript
- Wave Life Sciences Ltd. (NASDAQ:WVE ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Salim Syed - Mizuho Joon Lee - Truist Securities Mani Foroohar - SVB Securities Operator Good morning, and welcome to the Wave Life Sciences' Third Quarter 2022 Financial Results Conference Call.
- 11/10/2022
|
Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference
- CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Stifel 2022 Healthcare Conference in New York City on Wednesday, November 16, 2022, at 3:35 p.m. ET.
- 11/09/2022
|
Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022
- CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, November 10, 2022, to discuss the company's third quarter 2022 financial results and provide a business update.
- 11/03/2022
|
Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock?
- Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 10/17/2022
|
Best Penny Stocks To Buy? 3 To Watch During The Stock Market Crash
- Biotech penny stocks for your watch list this week. The post Best Penny Stocks To Buy?
- 10/10/2022
|
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch
- Best penny stocks to buy? Biotech penny stocks are heating up & these 4 might be worth watching now.
- 10/07/2022
|
Wave Life Sciences to Present at Chardan's 6th Annual Genetic Medicines Conference
- CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan's 6th Annual Genetic Medicines Conference in New York City on Tuesday, October 4, 2022, at 3:15 p.m. ET.
- 09/27/2022
|
Wave Therapeutics (WVE) Up on Update From Huntington's Study
- Wave Therapeutics (WVE) provides a positive update from its ongoing phase Ib/IIa study evaluating one of its lead candidates, WVE-003, for Huntington's disease. Stock up.
- 09/21/2022
|
Why Wave Life Sciences Was Zooming Higher Today
- The company says it has enough dosh on hand to carry it through this and next year.
- 08/11/2022
|
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2022 Results - Earnings Call Transcript
- Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President and Chief Executive Officer Mike Panzara - Chief Medical Officer Head, Therapeutics Discovery and Development Chandra Vargeese - Chief Technology Officer, Head of Platform Discovery Sciences Kyle Moran - Chief Financial Officer Conference Call Participants Salim Syed - Mizuho Luca Issi - RBC Mary Hodge - Truist Operator Good morning and welcome to the Wave Life Sciences' Second Quarter 2022 Financial Results and Business Update Conference Call.
- 08/11/2022
|
Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference
- CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 2022 Jefferies Healthcare Conference in New York City on Wednesday, June 8, 2022, at 3:00 p.m. ET.
- 05/25/2022
|
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q1 2022 Results - Earnings Call Transcript
- Wave Life Sciences Ltd. (NASDAQ:WVE ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President and Chief Executive Officer Mike Panzara - Chief Medical Officer, Head, Therapeutics Discovery and Development Kyle Moran - Chief Financial Officer Conference Call Participants Joon Lee - Truist Securities Salim Syed - Mizuho Lisa Walter - RBC Alex Thompson - Stifel Mani Foroohar - SVB Securities Suji Jeong - Jefferies Operator Good morning and welcome to the Wave Life Sciences First Quarter 2022 Financial Results Call.
- 05/12/2022
|
Wave Life Sciences to Present at Upcoming Investor Conferences
- CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investors conferences in May.
- 05/10/2022
|
Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022
- CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 12, 2022, to discuss the company's first quarter 2022 financial results and provide a business update.
- 05/05/2022
|
Wave Life Sciences to Present at Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, and Sri Vaddeboina, PhD, Senior Vice President, Chemistry, Manufacturing and Controls, are scheduled to participate virtually in an analyst-led fireside chat at Chardan's 6th Annual Genetic Medicines & Cell Therapy Manufacturing Summit on Tuesday, April 26, 2022, at 2:30 p.m. ET.
- 04/19/2022
|
Wave Life Sciences Jump As Low Doses of WVE-004 Lowers Disease Biomarker In Neurological Indications
- Wave Life Sciences Ltd's (NASDAQ: WVE) FOCUS-C9 study of WVE-004 shows reductions of poly(GP) dipeptide repeat proteins in cerebrospinal fluid (CSF) with low, single doses of WVE-004. The Phase 1b/2a trial is assessing WVE-004 in C9orf72-associated amyotrophic lateral.
- 04/04/2022
|
Wave Life Sciences to Present at Stifel 2022 CNS Days
- CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate virtually in an analyst-led fireside chat at the Stifel 2022 CNS Days event on Monday, March 28, 2022, at 9:15 a.m. EDT.
- 03/21/2022
|
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q4 2021 Results - Earnings Call Transcript
- Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q4 2021 Results - Earnings Call Transcript
- 03/03/2022
|
Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates
- Wave Life Sciences (WVE) delivered earnings and revenue surprises of -29.79% and 90.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/03/2022
|
Wave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022
- CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Virtual 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 10:40 a.m. ET.
- 02/09/2022
|
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2021 Results - Earnings Call Transcript
- Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2021 Results - Earnings Call Transcript
- 11/10/2021
|
Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021
- CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, November 10, 2021, to discuss its third quarter 2021 financial results and provide a business update.
- 11/01/2021
|
Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs
- Wave Life Sciences Ltd (NASDAQ: WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK) to discontinue discovery & research of preclinical programs for central nervous system (CNS) indications over a four-year research term. Under terms of the amendment, Takeda will pay Wave $22.5 million for collaboration-related research and preclinical expenses.
- 10/19/2021
|
Wave Life Sciences and Takeda Amend CNS Collaboration
- Amendment to ongoing collaboration allows Wave to advance or partner CNS programs, including those using ADAR editing
- 10/18/2021
|
Wave Life Sciences Shows Durable ADAR-Editing In Multiple Tissues In Animal Studies
- Wave Life Sciences Ltd (NASDAQ: WVE) presented new preclinical data for its ADAR-mediated RNA editing capability (ADAR editing) and an update on its discovery-stage alpha-1 antitrypsin deficiency (AATD) program. Related Link: Wave Life Sciences' RNA Editing Platform Shows Restoration of Functional AAT Protein in Preclinical Study
- 09/29/2021
|
Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast
- Durable ADAR editing in vivo in preclinical models, including in CNS tissues with editing out to at least four months
- 09/28/2021
|
Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference
- CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan Virtual Genetic Medicines Conference on Monday, October 4, 2021 at 2:00 p.m. ET.
- 09/22/2021
|
Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor Research Webcast on September 28, 2021
- Live webcast scheduled for Tuesday, September 28, 2021 at 10:00 a.m. EDT Live webcast scheduled for Tuesday, September 28, 2021 at 10:00 a.m. EDT
- 09/08/2021
|
Wave Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to give a pre-recorded presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, which will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. ET.
- 09/07/2021
|
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2021 Results - Earnings Call Transcript
- Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2021 Results - Earnings Call Transcript
- 08/08/2021
|
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
- Wave Life Sciences (WVE) delivered earnings and revenue surprises of -27.87% and -76.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2021
|
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
- Dosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD – first oligonucleotide using PN backbone chemistry modifications in clinical study
- 08/05/2021
|
Wave Life Sciences' RNA Editing Platform Shows Restoration of Functional AAT Protein in Preclinical Study
- Wave Life Sciences Ltd (NASDAQ: WVE) has announced the first proof-of-concept preclinical data for its ADAR (adenosine deaminases acting on RNA)-mediated RNA editing program in alpha-1 antitrypsin deficiency (AATD). AATD is a genetic disorder that may result in lung disease or liver disease.
- 06/03/2021
|
Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
- First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency
- 06/02/2021
|
Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference
- CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to give a presentation at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET. Dr. Bolno will provide a corporate update and discuss Wave's pipeline programs, including the first in vivo data from the company's ADAR editing discovery program for alpha-1 antitrypsin deficiency (AATD).
- 05/28/2021
|
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q1 2021 Results - Earnings Call Transcript
- Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q1 2021 Results - Earnings Call Transcript
- 05/13/2021
|
Recap: WAVE Life Sciences Q1 Earnings
- Shares of WAVE Life Sciences (NASDAQ:WVE) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 37.68% over the past year to ($0.86), which missed the estimate of ($0.59).
- 05/13/2021
|
Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update
- Clinical trials underway with next-generation candidates incorporating PN chemistry
- 05/13/2021
|
Wave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference
- CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer is scheduled to give a presentation at the RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 19, 2021 at 4:15 p.m. ET.
- 05/10/2021
|
Here's Why Wave Life Sciences Crashed Today
- No one ever said drug development was easy.
- 03/30/2021
|
WVE Stock Price Fell Over 20% Pre-Market: Why It Happened
- The stock price of Wave Life Sciences Ltd (NASDAQ: WVE) fell by over 20% pre-market. This is why it happened.
- 03/30/2021
|
Wave Life Sciences Stock Plunges After Antisense Oligonucleotide Candidates Disappoint In Huntington's Disease Study
- Wave Life Sciences Ltd's (NASDAQ: WVE) closely-watched antisense oligonucleotide program crashed in an early-stage Huntington's disease study, thus wiping out two experimental drug candidates. What Happened: WVE-120102 failed to separate from the placebo with no evidence of a dose-response on mutant Huntingtin protein (mHTT) at any of the doses.
- 03/30/2021
|
Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials
- mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101
- 03/29/2021
|
Are Options Traders Betting on a Big Move in Wave Life Sciences (WVE) Stock?
- Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.
- 03/23/2021
|
Wave Life Sciences to Present at the Third Annual Stifel CNS Day
- CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer and Michael Panzara, MD, MPH, Chief Medical Officer and Head of Therapeutics Discovery and Development are scheduled to participate virtually in an analyst-led fireside chat at the Third Annual Stifel CNS Day on Wednesday, April 1, 2021 at 11:30 a.m. ET.
- 03/19/2021
|
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q4 2020 Results - Earnings Call Transcript
- Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q4 2020 Results - Earnings Call Transcript
- 03/04/2021
|
Wave Life Sciences (WVE) Reports Q4 Loss, Lags Revenue Estimates
- Wave Life Sciences (WVE) delivered earnings and revenue surprises of -7.27% and -30.61%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/04/2021
|
Wave Life Sciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Strong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021
- 03/04/2021
|
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
- CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:00 a.m. ET on Thursday, March 4, 2021, to discuss its fourth quarter and full year 2020 financial results and provide a business update.
- 02/23/2021
|
Will Wave Life Sciences (WVE) Report Negative Q4 Earnings? What You Should Know
- Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/22/2021
|
Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference
- CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 5:00 p.m. ET.
- 02/16/2021
|
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2020 Results - Earnings Call Transcript
- Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2020 Results - Earnings Call Transcript
- 11/09/2020
|
Wave Life Sciences Reports Third Quarter 2020 Financial Results and Provides Business Update
- Results from all cohorts of PRECISION-HD1 and PRECISION-HD2 clinical trials and initial OLE data on track for 1Q 2021
- 11/09/2020
|
